Human Scientific Research HYPER-H21-1 evidences a speedy and sustained drop in blood strain with DehydraTECH-CBD and glorious tolerability
Kelowna, British Columbia – TheNewswire – July 29, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Firm” or “Lexaria”), a worldwide innovator in drug supply platforms is extraordinarily happy to challenge partial outcomes from human scientific research HYPER-H21-1 evaluating DehydraTECHTM-processed cannabidiol (“CBD”) for potential utility in opposition to hypertension. Partial outcomes associated to blood strain (“BP”) are being launched immediately, whereas further BP subset analyses and all different knowledge analyses together with pharmacokinetic (“PK”) evaluations and detailed blood chemistry work is in progress and shall be launched when full.
“We’re very inspired by these early ends in our 2021 hypertension program,” mentioned Chris Bunka, CEO of Lexaria. “Lexaria’s expertise enabled a speedy and sustained drop in blood strain, particularly systolic strain and significantly in Stage 2 hypertensive volunteers.”
Lead investigator Dr. Phil Ainslie, Professor, College of Well being and Train Sciences and Co-Director, Centre for Coronary heart, Lung & Vascular Well being College of British Columbia Okanagan, and Canada Analysis Chair in Cerebrovascular Physiology, commented that, “these early outcomes are extraordinarily promising on this at-risk hypertensive inhabitants and supply a basic assist for enlargement into extra extended repeat dosing and future long run scientific trials.”
BP was diminished throughout each female and male volunteers and was most pronounced with DehydraTECH-CBD within the first 10-50 minutes of the research, reinforcing our pre-existing findings demonstrating that DehydraTECH delivers superior efficiency over generic CBD controls.
Blood strain discount from baseline was best when measured by way of systolic strain. Within the subset of volunteers who had been Stage 2 hypertensive, peak systolic BP reductions from baseline had been noticed of as a lot as roughly 13 mmHg by the 50-minute time level with DehydraTECH-CBD, and systolic BP remained depressed all through nearly all the 3-hour period of the research. For reference, other studies of coronary coronary heart illness (“CHD”) have concluded that “decreasing systolic pressure by 10 mm Hg or diastolic strain by 5 mm Hg utilizing any of the principle courses of medication diminished CHD occasions (deadly and nonfatal) by a few quarter and stroke by a few third, whatever the presence or absence of vascular illness and of pretreatment BP. Coronary heart failure can be diminished by about 25%.”
There was additionally a bent for a higher discount in relative diastolic strain from baseline with DehydraTECH-CBD than the focus matched, generic CBD management (Fig 1). This was most notable within the preliminary 10-20 minute interval post-dosing evidencing statistical significance on the 20-minute timepoint (p=0.025).
Fig 1. Modifications in diastolic blood strain between generic CBD management (dose A) and DehydraTECH-CBD (dose B). Knowledge are grouped means (n=24) with linear regression.
As effectively, there was a bent for relative Imply Arterial Strain (“MAP”) to be diminished higher from baseline with the DehydraTECH-CBD than the focus matched, generic CBD management; once more, most notably within the preliminary 20 minutes post-dosing (Fig 2.). By comparability, in Lexaria’s 2018 human clinical study, 120 minutes had been required to attain the identical degree of MAP discount, demonstrating superior rapidity of onset of the “DehydraTECH 2.0” CBD formulation used within the current research comparatively talking.
Fig 2. Modifications in imply arterial blood strain between generic CBD management (dose A) and DehydraTECH-CBD (dose B). Knowledge are grouped means (n=24) with linear regression.
Lexaria was additionally happy that its DehydraTECH-CBD was effectively tolerated by all topics, with no critical antagonistic occasions or unintended effects noticed or reported. Ingestion of the concentration-matched, generic CBD management, alternatively, resulted in undesirable unintended effects in a number of the volunteers, specifically gastrointestinal misery together with diarrhea. These findings corroborate what Lexaria has beforehand evidenced in different unrelated research whereby human volunteers have additionally skilled diminished unintended effects with DehydraTECH-processed take a look at articles in comparison with concentration-matched, generic controls.
Lexaria appears ahead to finishing its ongoing further pattern and knowledge analyses work for this research and reporting upon these outcomes when full. Lexaria’s second human scientific hypertension research of 2021, research HYPER-H21-2, has accomplished dosing as beforehand reported and, in that research, three separate doses of DehydraTECH-CBD (150mg per dose) had been used, administered evenly over the course of a 24-hour monitoring interval. Based mostly on the BP decreasing developments witnessed within the current research, Lexaria is optimistic that repeat dosing similar to this over a sustained interval might additional improve efficacy. The outcomes of those two research shall be rigorously evaluated and regarded earlier than Lexaria’s third deliberate human scientific hypertension research of 2021 begins, anticipated this Fall. Lexaria is evaluating research concerns for a fourth, expanded, randomized, managed human scientific hypertension trial, with a view to constructing upon the outcomes of present investigations in a bigger inhabitants for enhanced statistical and scientific significance.
About Human Research HYPER-H21-1
Human Research HYPER-H21-1 was carried out at a European medical analysis hospital. Twenty-four human volunteers aged 45-65 with in any other case untreated pre- or mild-hypertension got both a single 300mg dose of generic CBD, or a single 300mg dose of DehydraTECH-CBD and studied over a 3-hour period. The load of the typical girl within the research was 178 lbs, and the load of the typical man within the research was 223 kilos. Blood strain and coronary heart price analyses had been taken each 10 minutes and pace and price of absorption of the CBD and its foremost metabolites (PK assessments) had been additionally assessed in the course of the research. Secondary analyses that shall be reported when full embody analysis of inflammatory and oxidative markers related to heart problems and gold-standard biomarkers of nitric oxide. This latter measure offers mechanistic perception into the discount in blood strain by way of vasodilation.
Inflammatory marker assessments might also be relevant to Lexaria’s analysis initiatives within the antiviral therapeutics area whereby efficient anti-inflammatory therapies are additionally helpful in treating ailments like COVID-19 or different widespread pro-inflammatory circumstances, the place Lexaria has already efficiently demonstrated DehydraTECH utility with one such anti-inflammatory drug, colchicine, used for COVID-19 remedy immediately as beforehand reported.
CBD within the Regulatory Setting.
CBD beneath the model title Epidiolex was accredited by the FDA in June 2018 for treating sure forms of pediatric seizure problems. Really useful dosing of Epidiolex CBD is 2.5mg per kilogram of body weight to start remedy, taken twice per day, growing to five.0mg per kilogram of body weight, taken twice per day. A mean 9 year-old baby weighs about 28 kg, so the FDA really useful dose of Epidiolex would initially be 140mg, growing to 280mg every day for long run use. The common grownup man within the US weighs 199.6 lbs (90.7kg), so if he was utilizing CBD at that very same price, he would require 900mg per day for a sustainable dose. The utmost FDA-approved dose of Epidiolex is 10.0mg per kilogram of body weight, taken twice every day.
The Hypertension market is valued at $28 billion per year and is anticipated to proceed rising as one of many world’s prime well being issues. Geographically, a number of the highest charges of development are anticipated in additional lately industrialized nations similar to China and India. Over 1.1 billion people worldwide undergo from hypertension – elevated blood strain.
“Amongst individuals 50 years of age or older, remoted systolic hypertension is the most typical type of hypertension, and systolic blood strain turns into extra vital than diastolic blood strain as an unbiased danger predictor for coronary occasions, stroke, coronary heart failure, and end-stage renal illness (ESRD). The World Burden of Illness Research recognized elevated blood strain because the main danger issue, amongst 67 studied, for loss of life and disability-adjusted life-years lost during 2010.“
Medication centered on blood strain and associated circumstances are a number of the highest selling drugs on the planet. Lipitor, used to deal with excessive ldl cholesterol and cut back the chance of coronary heart illness, has generated $94.7 billion in income from 1992 till 2017. Plavix is used to forestall coronary heart assault and stroke, has offered $46.5 billion from 1992 till 2017. There are several hypertension drugs that every generate $1 billion per 12 months or extra in income.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-viral drugs, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.